American Association for Cancer Research

SHERPA: Unknown

People

  1. Dang
    Dang
  2. Hudis
    Hudis
  3. Norton
    Norton
  4. Lake
    Lake
  5. D'Andrea-Carlino
    D'Andrea-Carlino
  6. Modi
    Modi
  7. Fornier
    Fornier
  8. Seidman
    Seidman
  9. Steingart
    Steingart
  10. Sugarman
    Sugarman

Groups

  1. Breast Medicine Service (49)
  2. Department of Medicine (49)
  3. Solid Tumor Oncology Division (49)
  4. Survivorship Research (49)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (21)
  6. Population Sciences Research Program (18)
  7. Epidemiology and Biostatistics (17)
  8. Biostatistics Service (15)
  9. Division of Subspecialty Medicine (12)
  10. Cardiology (11)
Search Within
  1. "Chau Dang"
Formats
  1. Meeting Abstract (41)
  2. Journal Article (8)
Groups
  1. Breast Medicine Service (49)
  2. Department of Medicine (49)
  3. Solid Tumor Oncology Division (49)
  4. Survivorship Research (49)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (21)
  6. Population Sciences Research Program (18)

More Groups

People
  1. Chau Dang (49)
  2. Clifford Hudis (27)
  3. Larry Norton (19)
  4. Maura Dickler (14)
  5. Diana Lake (12)
  6. Sujata Patil (12)

More People

Years
  1. 2023 (1)
  2. 2020 (6)
  3. 2019 (3)
  4. 2018 (7)
  5. 2017 (3)
  6. 2016 (6)

More Years

Publications
  1. Cancer Research (42)
  2. Clinical Cancer Research (7)

Results (49)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cytochrome P450 oxidoreductase (POR) associated with severe paclitaxel-induced peripheral neuropathy in patients of European ancestry from ECOG-ACRIN E5103
    Journal Article

    Shen, F.; Jiang, G.; Philips, S.; Gardner, L.; Xue, G.; Cantor, E.; Ly, R. C.; Osei, W.; Wu, X.; Dang, C.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)
    Meeting Abstract

    Tolaney, S. M.; Trippa, L.; Barry, W.; Hu, J.; Dang, C.; Yardley, D.; Isakoff, S.; Valero, V.; Faggen, M.; Mulvey, T.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Disease free survival rate with dose dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab (ddACTHP) in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Patil, S.; Norton, L.; Robson, M.; Dang, C.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis
    Meeting Abstract

    Swain, S. M.; Macharia, H.; Cortes, J.; Dang, C.; Gianni, L.; Hurvitz, S.; Jackisch, C.; Schneeweiss, A.; Slamon, D.; Valagussa, P.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • The genomic landscape of breast cancer in African American women
    Meeting Abstract

    Serna-Tamayo, C.; Drago, J. Z.; Dos Anjos, C.; Herbert, J.; Pareja, F.; Modi, S.; Jhaveri, K.; Dang, C.; Solit, D. B.; Norton, L.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial)
    Meeting Abstract

    Ruddy, K. J.; Trippa, L.; Hu, J.; Barry, W. T.; Dang, C. T.; Yardley, D. A.; Isakoff, S. J.; Valero, V. V.; Faggen, M. G.; Mulvey, T. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab (TH) (ATEMPT) trial (TBCRC 033)
    Meeting Abstract

    Partridge, A.; Zheng, Y.; Rosenberg, S.; Gelber, R.; Gelber, S.; Barry, W.; Dang, C.; Yardley, D.; Isakoff, S.; Valero, V.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Wang, R.; Singh, J.; Sterlin, V.; Goldstein, M.; Lake, D.; Wong, S.; Baselga, J.; Norton, L.; Dang, C.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • The impact of breast cancer surgery on quality of life: Long term results from E5103
    Meeting Abstract

    Rosenberg, S. M.; O'Neill, A.; Sepucha, K.; Miller, K. D.; Dang, C. T.; Northfelt, D. W.; Sledge, G. W.; Schneider, B. P.; Partridge, A. H.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer
    Meeting Abstract

    Tanioka, M.; Parker, J. S.; Henry, L. N.; Tolaney, S.; Dang, C.; Krop, I. E.; Harris, L.; Polley, M.; Berry, D. A.; Winer, E. P.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: